Beranda › Kanker Kandung Kemih › Texas › Dallas
Uji klinis Kanker Kandung Kemih di Dallas, TX
27 studi untuk Kanker Kandung Kemih mencari peserta di lokasi sekitar Dallas (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
Menerima pesertaFase 2
- Parkland Memorial Hospital, Dallas
- UT Southwestern Simmons Cancer Center - RedBird, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
Enfortumab Vedotin and Stereotactic Radiation for Localized Bladder Cancer
Menerima pesertaFase 1/2
- UT Southwestern Medical Center, Dallas
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Menerima pesertaFase 2
- UT Southwestern Simmons Cancer Center - RedBird, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
Menerima pesertaFase 1
- Cancer Center Outpatient Building, Dallas
- The University of Texas Southwestern Medical Center, Dallas
- UT Southwestern Medical Center - West Campus Building, Dallas
- dan 2 lainnya
DESTINY-PANTUMOUR04
Menerima pesertaStudi observasional
- Research Site, Dallas
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Menerima pesertaFase 3
- Parkland Health and Hospital System, Dallas
- UT Southwestern Medical Center, Dallas
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Menerima pesertaStudi observasional
- UT Southwestern Medical Center, Dallas
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
Menerima pesertaFase 2
- Urology Clinics of North Texas, PLLC, Dallas
- UT Southwestern Medical Center, Dallas
Artificial Intelligence Prediction Tool in Non-muscle Invasive Bladder Cancer (NMIBC)
Menerima pesertaStudi observasional
- University of Texas Southwestern Medical Center, Dallas
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
Menerima pesertaFase 1
- University of Texas Southwestern, Dallas
- Texas Oncology, P.A, Dallas
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
Menerima pesertaFase 2/3
- Research Site, Dallas
Measuring Surgical Recovery After Radical Cystectomy
Menerima pesertaStudi observasional
- University of Texas - Southwestern, Dallas
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
Menerima pesertaFase 3
- Parkland Memorial Hospital, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
Menerima pesertaFase 1/2
- UT Southwestern Medical Center, Dallas
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Menerima pesertaFase 2
- Baylor Scott & White Research Institute, Dallas
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
Menerima pesertaFase 3
- Research Site, Dallas
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Menerima pesertaFase 2
- Baylor Scott and White Research Institute, Dallas
A First in Human Study of PLT012 in Participants With Solid Tumor Cancers
Menerima pesertaFase 1
- NEXT Dallas, Dallas
Predicting BCG Response
Menerima pesertaStudi observasional
- University of Texas Southwestern, Dallas
Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine.
Menerima peserta
- UT Southwestern Medical Center, Dallas
Specimen Collection for Validation of UroAmp: A Next Generation Sequencing Platform for Detection and Surveillance of Bladder Cancer
Menerima pesertaStudi observasional
- UT Southwestern Medical Center, Dallas
Bladder Cancer Screening Trial
Menerima peserta
- University of Texas Southwestern Medical Center, Dallas
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
Menerima pesertaFase 1/2
- NEXT Oncology - Dallas, Dallas
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Menerima pesertaFase 1
- Mary Crowley Cancer Research, Dallas
- Baylor University Medical Center, Dallas
A Novel Multiplex ELISA Assay for Evaluating Patients With Microscopic Hematuria for Bladder Cancer
Menerima pesertaStudi observasional
- UT Southwestern Medical Center at Dallas, Dallas
Blue Light Cystoscopy With Cysview® Registry
Menerima pesertaStudi observasional
- UT Southwestern, Dallas
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Menerima pesertaStudi observasional
- Massive Bio SYNERGY-AI site, Dallas
Uji klinis Kanker Kandung Kemih di kota lain
- New York City, NY35 studi
- Nashville, TN31 studi
- Houston, TX31 studi
- Boston, MA26 studi
- Washington, DC26 studi
- Los Angeles, CA24 studi
- Baltimore, MD24 studi
- St. Louis, MO22 studi
- Philadelphia, PA21 studi
- Seattle, WA21 studi
- Edison, NJ21 studi
- Chicago, IL21 studi
Studi lain di Dallas
- Kanker Payudara55 studi
- Kanker Paru Non-Sel Kecil52 studi
- Kanker Metastatik42 studi
- Gagal Jantung42 studi
- Kanker (semua jenis)37 studi
- Kanker Prostat36 studi
- Kanker Kolorektal33 studi
- Obesitas30 studi
- Kanker Ovarium28 studi
- Kanker Paru27 studi
- Kanker Endometrium24 studi
- Penyakit Kardiovaskular23 studi
Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.